D. Kyle Hogarth

Prof. D. Kyle Hogarth


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Chest
Verified
Journal Article
Closed access
KDKaren C. Dugan
Karen C. Dugan
BLBalaji Laxmanan
Balaji Laxmanan
SMSeptimiu Murgu
Septimiu Murgu
DHD. Kyle Hogarth
D. Kyle Hogarth

1 December 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MWMichael E. Wechsler
Michael E. Wechsler
MLMichel Laviolette
Michel Laviolette
ARAdalberto S. Rubin
Adalberto S. Rubin
JFJussara Fiterman
Jussara Fiterman
JSJOSE R. LAPA E SILVA
JOSE R. LAPA E SILVA
MCMario Castro
Mario Castro

11 December 2019 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
UCUdit Chaddha
Udit Chaddha
SKStephen P. Kovacs
Stephen P. Kovacs
CMChristopher Manley
Christopher Manley
DHD. Kyle Hogarth
D. Kyle Hogarth
GCGustavo Cumbo-Nacheli
Gustavo Cumbo-Nacheli
SMSeptimiu Murgu
Septimiu Murgu
Background: The Robotic Endoscopic System (Auris Health, Inc., Redwood City, CA) has the potential to overcome several limitations of contemporary guided-bronchoscopic technologies for the diagnosis of lung lesions. Our objective is to report on the initial post-marketing feasibility, safety and diagnostic yield of this technology.Methods: We retrospectively reviewed data on consecutive cases in which robot-assisted bronchoscopy was used to sample lung lesions at four centers in the US (academic and community) from June 15th, 2018 to December 15th, 2018.Results: One hundred and sixty-seven lesions in 165 patients were included in the analysis, with an average follow-up of 185 ± 55 days. The average size of target lesions was 25.0 ± 15.0 mm. Seventy-one percent were located in the peripheral third of the lung. Pneumothorax and airway bleeding occurred in 3.6 and 2.4% cases, respectively. Navigation was successful in 88.6% of cases. Tissue samples were successfully obtained in 98.8%. The diagnostic yield estimates ranged from 69.1 to 77% assuming the cases of biopsy-proven inflammation without any follow-up information (N = 13) were non-diagnostic and diagnostic, respectively. The yield was 81.5, 71.7 and 26.9% for concentric, eccentric and absent r-EBUS views, respectively. Diagnostic yield was not affected by lesion size, density, lobar location or centrality.Conclusions: RAB implementation in community and academic centers is safe and feasible, with an initial diagnostic yield of 69.1–77% in patients with lung lesions that require diagnostic bronchoscopy. Comparative trials with the existing bronchoscopic technologies are needed to determine cost-effectiveness of this technology.

20 December 2012 in Journal of Asthma
Verified
Journal Article
Closed access
PDF file
DDDiana C. Doeing
Diana C. Doeing
AMAmit K. Mahajan
Amit K. Mahajan
SWSteven R. White
Steven R. White
ENEdward T. Naureckas
Edward T. Naureckas
JKJerry A. Krishnan
Jerry A. Krishnan
DHD. Kyle Hogarth
D. Kyle Hogarth
Objective. Bronchial thermoplasty (BT) can provide relief for patients with severe, uncontrolled asthma despite maximal medical therapy. However, it is unclear whether BT is safe in patients with very severe airflow obstruction. Methods. We performed BT in eight patients with severe asthma as defined by Expert Panel Report 3 (EPR-3) guidelines who were poorly controlled despite step 5 therapy. Data were available on each subject for 1 year prior to and 15–72 weeks following BT. Results. The mean (±SEM) pre-bronchodilator forced expiratory volume in one second (FEV1) prior to BT was 51.8 ± 8.6% of predicted, and the mean (±SEM) number of hospitalizations for asthma in the year prior to BT was 2.9 ± 1.2. No subject had an unexpected severe adverse event due to BT. Among the eight patients with follow-up of at least 15 weeks, there was no significant decline in FEV1 (p = .4). Conclusion. We suggest that BT may be safe for asthma patients with severe airflow obstruction and higher hospitalization rates than previously reported.

1 April 2008 in Chest
Verified
Journal Article
Closed access
PDF file
DHD. Kyle Hogarth
D. Kyle Hogarth
GRGary Rachelefsky
Gary Rachelefsky

19 April 2023 in Journal of Bronchology & Interventional Pulmonology
Verified
Journal Article
Open access
KBKrish Bhadra
Krish Bhadra
OROtis B. Do Rickman
Otis B. Do Rickman
AMAmit K. Mahajan
Amit K. Mahajan
DHD. Kyle Hogarth
D. Kyle Hogarth
Background: The Galaxy System (Noah Medical) is a novel robotic endoluminal platform using electromagnetic navigation combined with integrated tomosynthesis technology and augmented fluoroscopy. It provides intraprocedural imaging to correct computerized tomography (CT) to body divergence and novel confirmation of tool-in-lesion (TIL). The primary aim of this study was to assess the TIL accuracy of the robotic bronchoscope with integrated digital tomosynthesis and augmented fluoroscopy. Methods: Four operators conducted the experiment using 4 pigs. Each physician performed between 4 and 6 nodule biopsies for 20 simulated lung nodules with purple dye and a radio pacifier. Using Galaxy’s “Tool-in-Lesion Tomography (TOMO+)” with augmented fluoroscopy, the physician navigated to the lung nodules, and a tool (needle) was placed into the lesion. TIL was defined by the needle in the lesion determined by cone-beam CT. Results: The lung nodule’s average size was 16.3 ± 0.97 mm and was predominantly in the lower lobes (65%). All 4 operators successfully navigated to all (100%) of the lesions in an average of 3 minutes and 39 seconds. The median number of tomosynthesis sweeps was 3 and augmented fluoroscopy was utilized in most cases (17/20 or 85%). TIL after the final TOMO sweep was 95% (19/20) and tool-touch-lesion was 5% (1/20). Biopsy yielding purple pigmentation was also 100% (20/20). Conclusion: The Galaxy System demonstrated successful digital TOMO confirmed TIL success in 95% (19/20) of lesions and tool-touch-lesion in 5% (1/20) as confirmed by cone-beam CT. Successful diagnostic yield was achieved in 100% (20/20) of lesions as confirmed by intralesional pigment acquisition.